Literature DB >> 2191148

Generation of seal influenza virus variants pathogenic for chickens, because of hemagglutinin cleavage site changes.

S Q Li1, M Orlich, R Rott.   

Abstract

Influenza virus A/seal/Mass/1/80 (H7N7) was adapted to grow in MDCK cells and chicken embryo cells (CEC) in the absence of exogenous protease. The biological properties of the virus variants obtained coincided with intracellular activation of the hemagglutinin (HA) by posttranslational proteolytic cleavage and depended on the cell type used for adaptation. MDCK cell-adapted variants contained point mutations in regions of the HA more distant from the cleavage site. It is proposed that these mutations are probably responsible, through an unknown mechanism, for enhanced cleavability of HA in MDCK cells. Such virus variants were apathogenic in chickens. CEC-adapted variants, on the other hand, contained an insertion of basic amino acids at the HA cleavage site, in addition to scattered point mutations. The insertions converted the cleavage sites in the variant virus HAs so that they came to resemble the cleavage site found in highly pathogenic avian influenza viruses. CEC variants with such cleavage site modifications were highly pathogenic for chickens. The lethal outcome of the infection in chickens demonstrated for the first time that an influenza virus derived from a mammalian species can be modified during adaptation to a new cell type to such an extent that the resulting virus variant becomes pathogenic for an avian species.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2191148      PMCID: PMC249560     

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  26 in total

1.  Enhancement of the infectivity of influenza A and B viruses by proteolytic cleavage of the hemagglutinin polypeptide.

Authors:  S G Lazarowitz; P W Choppin
Journal:  Virology       Date:  1975-12       Impact factor: 3.616

2.  Analysis of the relationship between cleavability of a paramyxovirus fusion protein and length of the connecting peptide.

Authors:  R G Paterson; M A Shaughnessy; R A Lamb
Journal:  J Virol       Date:  1989-03       Impact factor: 5.103

3.  Activation of influenza A viruses by trypsin treatment.

Authors:  H D Klenk; R Rott; M Orlich; J Blödorn
Journal:  Virology       Date:  1975-12       Impact factor: 3.616

4.  Mutations at the cleavage site of the hemagglutinin after the pathogenicity of influenza virus A/chick/Penn/83 (H5N2).

Authors:  M Ohuchi; M Orlich; R Ohuchi; B E Simpson; W Garten; H D Klenk; R Rott
Journal:  Virology       Date:  1989-02       Impact factor: 3.616

5.  The structure of the hemagglutinin, a determinant for the pathogenicity of influenza viruses.

Authors:  F X Bosch; M Orlich; H D Klenk; R Rott
Journal:  Virology       Date:  1979-05       Impact factor: 3.616

6.  Structure of the haemagglutinin membrane glycoprotein of influenza virus at 3 A resolution.

Authors:  I A Wilson; J J Skehel; D C Wiley
Journal:  Nature       Date:  1981-01-29       Impact factor: 49.962

7.  Characterization of an influenza A virus from seals.

Authors:  R G Webster; V S Hinshaw; W J Bean; K L Van Wyke; J R Geraci; D J St Aubin; G Petursson
Journal:  Virology       Date:  1981-09       Impact factor: 3.616

8.  Cleavability of hemagglutinin determines spread of avian influenza viruses in the chorioallantoic membrane of chicken embryo.

Authors:  R Rott; M Reinacher; M Orlich; H D Klenk
Journal:  Arch Virol       Date:  1980       Impact factor: 2.574

9.  Conjunctivitis in human beings caused by influenza A virus of seals.

Authors:  R G Webster; J Geraci; G Petursson; K Skirnisson
Journal:  N Engl J Med       Date:  1981-04-09       Impact factor: 91.245

10.  DNA sequencing with chain-terminating inhibitors.

Authors:  F Sanger; S Nicklen; A R Coulson
Journal:  Proc Natl Acad Sci U S A       Date:  1977-12       Impact factor: 11.205

View more
  35 in total

1.  A novel eight amino acid insertion contributes to the hemagglutinin cleavability and the virulence of a highly pathogenic avian influenza A (H7N3) virus in mice.

Authors:  Xiangjie Sun; Jessica A Belser; Terrence M Tumpey
Journal:  Virology       Date:  2015-11-26       Impact factor: 3.616

2.  The Influenza A Virus Genotype Determines the Antiviral Function of NF-κB.

Authors:  Sharmistha Dam; Michael Kracht; Stephan Pleschka; M Lienhard Schmitz
Journal:  J Virol       Date:  2016-08-12       Impact factor: 5.103

3.  Pathogenicity of influenza A/Seal/Mass/1/80 virus mutants for mammalian species.

Authors:  H Scheiblauer; A P Kendal; R Rott
Journal:  Arch Virol       Date:  1995       Impact factor: 2.574

Review 4.  Protease-dependent virus tropism and pathogenicity.

Authors:  Y Nagai
Journal:  Trends Microbiol       Date:  1993-06       Impact factor: 17.079

5.  The viral polymerase mediates adaptation of an avian influenza virus to a mammalian host.

Authors:  G Gabriel; B Dauber; T Wolff; O Planz; H-D Klenk; J Stech
Journal:  Proc Natl Acad Sci U S A       Date:  2005-12-08       Impact factor: 11.205

Review 6.  Influenza Virus Infection of Marine Mammals.

Authors:  Sasan Fereidouni; Olga Munoz; Sophie Von Dobschuetz; Marco De Nardi
Journal:  Ecohealth       Date:  2014-09-18       Impact factor: 3.184

7.  Structural features influencing hemagglutinin cleavability in a human influenza A virus.

Authors:  Y Kawaoka
Journal:  J Virol       Date:  1991-03       Impact factor: 5.103

Review 8.  Human health implications of avian influenza viruses and paramyxoviruses.

Authors:  I Capua; D J Alexander
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2003-12-09       Impact factor: 3.267

9.  Reverse genetics provides direct evidence for a correlation of hemagglutinin cleavability and virulence of an avian influenza A virus.

Authors:  T Horimoto; Y Kawaoka
Journal:  J Virol       Date:  1994-05       Impact factor: 5.103

10.  Thermolysin activation mutants with changes in the fusogenic region of an influenza virus hemagglutinin.

Authors:  M Orlich; R Rott
Journal:  J Virol       Date:  1994-11       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.